Table 9. Treatment Approaches for Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Chemotherapy (No. of Cycles)aRadiation (Gy)No. of PatientsEvent-Free Survival (No. of Years of Follow-up)Survival (No. of Years of Follow-up)
COPP/ABV (4)b [20]None 5296% (10)N/A
IFRT (21)3596% (10)
CVP (3) [50]None5574% (5)100% (5)
DBVE (2–4)c [48]None2694% (8)100% (8)
IFRT (25.5)
VAMP (4)c [54]None 26 89.4% (5)N/A
IFRT (25)685.7% (5)N/A
VAMP (4) [46] IFRT (15–25.5) 33 100% (10)100% (10)
Noned [24] Noned 5277% (5)100% (5)
AV-PC [24]None12485.5% (5)100% (5)
IFRT (21)11
Nonee [25] None 5167% (2)100% (2)

IFRT = involved-field radiation therapy; N/A = not applicable; No. = number.

aRefer to Table 5 for more information about the chemotherapy regimens.

bAllocation to radiation therapy or no radiation therapy was based on response to therapy. These results were for the group of patients with mixed-cellularity histology and nodular lymphocyte-predominant Hodgkin lymphoma.

cAllocation was based on clinical response.

dSingle lymph node surgically resected.

eAll involved lymph nodes surgically resected.

From: Childhood Hodgkin Lymphoma Treatment (PDQ®)

Cover of PDQ Cancer Information Summaries
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.